Abstract

The facets of host control during Plasmodium liver infection remain largely unknown. We find that the SLC7a11-GPX4 pathway, which has been associated with the production of reactive oxygen species, lipid peroxidation, and a form of cell death called ferroptosis, plays a critical role in control of Plasmodium liver stage infection. Specifically, blocking GPX4 or SLC7a11 dramatically reduces Plasmodium liver stage parasite infection. In contrast, blocking negative regulators of this pathway, NOX1 and TFR1, leads to an increase in liver stage infection. We have shown previously that increased levels of P53 reduces Plasmodium LS burden in an apoptosis-independent manner. Here, we demonstrate that increased P53 is unable to control parasite burden during NOX1 or TFR1 knockdown, or in the presence of ROS scavenging or when lipid peroxidation is blocked. Additionally, SLC7a11 inhibitors Erastin and Sorafenib reduce infection. Thus, blocking the host SLC7a11-GPX4 pathway serves to selectively elevate lipid peroxides in infected cells, which localize within the parasite and lead to the elimination of liver stage parasites.

Details

Title
Liver stage malaria infection is controlled by host regulators of lipid peroxidation
Author
Kain, Heather S 1 ; Glennon Elizabeth K K 2 ; Vijayan Kamalakannan 2 ; Arang Nadia 3   VIAFID ORCID Logo  ; Douglass, Alyse N 4 ; Fortin, Chelsea L 5   VIAFID ORCID Logo  ; Zuck Meghan 2 ; Lewis, Adam J 1 ; Whiteside, Samantha L 2 ; Dudgeon, Denali R 1 ; Johnson, Jarrod S 6 ; Aderem, Alan 7 ; Stevens, Kelly R 5 ; Kaushansky Alexis 8 

 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); Seattle Children’s Research Institute, Seattle, USA (GRID:grid.240741.4) (ISNI:0000 0000 9026 4165) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); University of California, Department of Biomedical Sciences, San Diego, La Jolla, USA (GRID:grid.53964.3d) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); University of Washington, Pathobiology Program, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 University of Washington, Departments of Bioengineering & Pathology, Institute for Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); University of Utah, Department of Biochemistry, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); Seattle Children’s Research Institute, Seattle, USA (GRID:grid.240741.4) (ISNI:0000 0000 9026 4165); University of Washington, Department of Immunology, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 Seattle Biomedical Research Institute, Center for Infectious Disease Research, Seattle, USA (GRID:grid.53964.3d) (ISNI:0000 0004 0463 2611); Seattle Children’s Research Institute, Seattle, USA (GRID:grid.240741.4) (ISNI:0000 0000 9026 4165); University of Washington, Department of Global Health, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
Pages
44-54
Publication year
2020
Publication date
Jan 2020
Publisher
Nature Publishing Group
ISSN
13509047
e-ISSN
14765403
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2327331905
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.